IND Approval Granted! Shibeikang's SBK017 Oral Solution Secures Clinical Trial Approval from NMPA

Recently, Chengdu Shibeikang Biomedical Technology Co., Ltd. (hereinafter referred to as "SBK") successfully obtained the Investigational New Drug (IND) approval notice (No.: 2025LP01862) from the National Medical Products Administration (NMPA) for its sindependently developed SBK017 Oral Solution, enabling the company to initiate clinical trials for this product.

SBK017 Oral Solution is intended for the treatment of ischemic cardiovascular diseases and ischemic cerebrovascular diseases caused by arteriosclerosis, venous thrombosis, as well as for thrombosis prevention during hemodialysis. Preclinical studies have revealed that this oral solution offers exceptional safety while significantly improving patient compliance, showcasingstrong potential for clinical application.

SBK will rigorously comply with national regulations to actively and systematically advance the clinical research process of SBK017 Oral Solution,aiming to provide a safer, more effective, and convenient therapeutic option that improves the treatment outlook for global patients with cardiovascular and cerebrovascular diseases.

The successful IND approval of SBK017 Oral Solution marks a significant milestone in SBK's innovative drug development and lays a solid foundation for its future product pipeline strategy.

In recent years, SBK has been constructing an internationally competitive independent R&D system, actively advancing global strategic deployment with a focus on disease domains such as cardiovascular and cerebrovascular diseases and respiratory system disorders. The company has established a global product pipeline featuring multiple investigational innovative drugs spanning all development stages, from preclinical to advanced clinical trials. Looking ahead, SBK will intensify its international expansion efforts, accelerating the commercialization of innovative drugs through in-house R&D to offer more therapeutic options and address critical unmet medical needs.

Founded in 2015, Chengdu Shibeikang Biomedical Technology Co., Ltd. is a research-driven company rooted in China, serving the world, dedicated to differentiated drug innovation. Guided by our mission of "Improving Public Health with Innovative Medicines and Caring Expertise", SBK is committed to the corporate values of "'People-centered', Driven by Change, Innovation at the Core". Guided by clinical needs, we pursue an innovation-driven strategy with a focus on differentiated R&D. Specializing in cardiovascular, cerebrovascular, and respiratory therapies, we are dedicated to become a global leader in the differentiated innovation of new drugs, to develop better medicines, broaden global access, and elevate human health through unwavering commitment.